🎁 Black Friday: up to 50% off of annual plans
Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
41.25
-5.40 (-11.58%)
At close: Nov 20, 2026

Pet Pharm Biotech Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
47.4524.9914.519.15-3.81
Depreciation & Amortization
45.3332.9918.2816.6714.23
Other Amortization
1.61.61.330.080.07
Loss (Gain) From Sale of Assets
----0.21
Asset Writedown & Restructuring Costs
----0.1
Stock-Based Compensation
2.120.620.020.01-
Provision & Write-off of Bad Debts
-0.060.02-0.03-1.21.2
Other Operating Activities
-0.9-0.91-2.32--
Change in Accounts Receivable
-2.5-19.02-2.51-9.13-8.53
Change in Inventory
-3.250.97-2.88-4.99-1.33
Change in Accounts Payable
-0.44-13.673.111.9-4.3
Change in Unearned Revenue
-0.740.510.370.85-0.24
Change in Other Net Operating Assets
6.866.21-0.977.43-15.42
Operating Cash Flow
95.4734.328.8820.75-17.83
Operating Cash Flow Growth
173.79%18.75%39.16%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Capital Expenditures
41.94-29.51-188.4-12.68-10.04
Sale of Property, Plant & Equipment
----1.5
Cash Acquisitions
--107.11---
Sale (Purchase) of Intangibles
--0.37-1.08--
Investment in Securities
59-44-65-91-50
Other Investing Activities
-221.41-220.63-8.46-30.10.48
Investing Cash Flow
-120.47-401.61-262.93-133.77-58.07

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Long-Term Debt Issued
-1.58100--
Short-Term Debt Repaid
-----4.05
Long-Term Debt Repaid
--109.38-7.03-5.25-3.78
Lease Payments
-11.56-9.17-7.03-5.25-3.66
Total Debt Repaid
-28.37-109.38-7.03-5.25-7.82
Net Debt Issued (Repaid)
14.22-107.892.97-5.25-7.82
Issuance of Common Stock
-567.03162.4227096.5
Common Dividends Paid
-14.31-5.05-8.04--
Other Financing Activities
-26.830.01---
Financing Cash Flow
-26.92454.18247.35264.7588.68

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
-51.9286.8713.3151.7312.78

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
137.414.79-159.518.08-27.87
Free Cash Flow Growth
-----
Free Cash Flow Margin
51.49%2.16%-122.05%6.85%-36.80%
Free Cash Flow Per Share
2.350.09-3.850.27-1.11
Levered Free Cash Flow
-81.45-2.7-25.09-84.79-
Unlevered Free Cash Flow
-80.55-2.14-24.98-84.69-
Free Cash Flow After Leases
125.85-4.38-166.552.83-31.53

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash Interest Paid
0.880.880.180.180.2
Cash Income Tax Paid
0.080.080.1--
Change in Working Capital
-0.06-25-2.89-3.95-29.82